Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with <sup>177</sup>Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization...

Full description

Bibliographic Details
Main Authors:	Tais Basaco, Stefanie Pektor, Josue M. Bermudez, Niurka Meneses, Manfred Heller, José A. Galván, Kayluz F. Boligán, Stefan Schürch, Stephan von Gunten, Andreas Türler, Matthias Miederer
Format:	Article
Language:	English
Published:	MDPI AG 2018-11-01
Series:	Pharmaceuticals
Subjects:	carbonic anhydrase IX girentuximab renal cell carcinomas <sup>177</sup>Lu-radiopharmaceuticals radioimmunotherapy
Online Access:	https://www.mdpi.com/1424-8247/11/4/132

Similar Items

Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody
by: Elgström Erika, et al.
Published: (2012-11-01)

Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agent for Colon Cancer
by: Radu Anton Leonte, et al.
Published: (2021-04-01)

<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans
by: Licia Uccelli, et al.
Published: (2021-09-01)

PSMA Theranostics: Science and Practice
by: Kgomotso Mokoala, et al.
Published: (2021-08-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Estudo da conjugação e radiomarcação do anticorpo monoclonal rituximab para aplicação em terapia radionuclídica
by: Adriana Vidal Fernandes Massicano
Published: (2011)

Estudo da conjugação e radiomarcação do anticorpo monoclonal rituximab para aplicação em terapia radionuclídica
by: Massicano, Adriana Vidal Fernandes
Published: (2011)

Lipidic Cubic-Phase Nanoparticles (Cubosomes) Loaded with Doxorubicin and Labeled with <sup>177</sup>Lu as a Potential Tool for Combined Chemo and Internal Radiotherapy for Cancers
by: Adrianna Cytryniak, et al.
Published: (2020-11-01)

Correlation of An Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)

Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties
by: Ana Cláudia Camargo Miranda, et al.
Published: (2021-06-01)

Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Sazan Rasul, et al.
Published: (2021-05-01)

Long‐Term Survival and Value of <sup>18</sup>F‐FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with <sup>177</sup>Lu‐DOTATATE
by: Margarida Rodrigues, et al.
Published: (2021-03-01)

Biomarkers in Prostate-Specific Membrane Antigen Theranostics
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-06-01)

Lutathera<sup>®</sup>: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
by: Ute Hennrich, et al.
Published: (2019-07-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
by: Ulrika Jahn, et al.
Published: (2021-02-01)

In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor
by: Christopher Montemagno, et al.
Published: (2021-03-01)

Production, quality control, biodistribution assessment and preliminary dose evaluation of [177Lu]-tetra phenyl porphyrin complex as a possible therapeutic agent
by: Samaneh Zolghadri, et al.
Published: (2015-06-01)

Spectral Comparison of Neutron-Irradiated Natural and Enriched Ytterbium Targets for Lu-177 Production
by: M. Maiyesni, et al.
Published: (2019-11-01)

Therapeutic Potential of <sup>47</sup>Sc in Comparison to <sup>177</sup>Lu and <sup>90</sup>Y: Preclinical Investigations
by: Klaudia Siwowska, et al.
Published: (2019-08-01)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

<sup>177</sup>Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α<sub>1</sub>-Microglobulin (A1M), Including Kidney Damage Assessment Using <sup>99m</sup>Tc-MAG3 Imaging
by: Amanda Kristiansson, et al.
Published: (2021-02-01)

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of <sup>177</sup>Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
by: Rashmi G. Shah, et al.
Published: (2021-01-01)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01)

Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [<sup>177</sup>Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model
by: Judith Anna Delage, et al.
Published: (2021-01-01)

Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute
by: Cristina Müller, et al.
Published: (2019-09-01)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with <sup>177</sup>Lu-DOTATATE
by: Achyut Ram Vyakaranam, et al.
Published: (2019-06-01)

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab
by: Lei Kang, et al.
Published: (2021-05-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021-06-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Radiolabeled Antibody Fragment for Preparation of (<sub>177</sub>Lu-DOTA)<sub>m</sub>-PAMAM G3.0-F(ab’)<sub>2</sub> trastuzumab as a Radiopharmaceutical for Cancer Therapy
by: R.D. Haryuni, et al.
Published: (2017-06-01)

Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
by: Egbert Oosterwijk, et al.
Published: (2013-05-01)

Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from 177Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts
by: Kwon Joong Yong, et al.
Published: (2016-05-01)

Inhibition of HIF-1α by Atorvastatin During <sup>131</sup>I-RTX Therapy in Burkitt’s Lymphoma Model
by: Eun-Ho Kim, et al.
Published: (2020-05-01)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
by: Young Sub Lee, et al.
Published: (2019-10-01)

Dissecting the Proton Transport Pathway in Oral Squamous Cell Carcinoma: State of the Art and Theranostics Implications
by: Alejandro I. Lorenzo-Pouso, et al.
Published: (2019-08-01)